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Results: The main result was the reduction in primary and 
nodal volumes due to better definition of lung mass and 
nearby lung Collapse , the latter could be easily defined in 14 
cases on the DW-MRI vs. 7 cases only by CT scans (P=0.016). 
Median GTV total (sum of 1ry and nodal GTV), on MRI 
Diffusion compared to that on the CT scan was 354 and 386 
cm3 respectively (P= 0.009). In 15 cases, a mean decrease in 
the GTV total of 34% ±56% (median, 9%; range, 0.2- 32.5%) by 
using DW-MRI. only in three other cases a mean increase in 
the GTV total of 12.7% ±14.9% (median, 9.7%; range, 0.4- 
221%). was found. The median PTVs on the CT scans vs. the 
MRI Diffusion were 1623 (range, 493–2965 cm3) & 1419 
(range, 542–3158 cm3) respectively which was statistically 
non significant (P= 0.391).  
 
Conclusion: This pilot prospective study concluded that DW-
MRI as a functional image can aid in proper definition and 
delineation of the target volumes after fusion of DWI and the 
CT images . GTV Total decreased in most cases due to 
exclusion of collapse, consolidation, reactionary and 
inflammatory LN, however GTV total was increased in 3/20 
patients due to better nodal detection and better 
visualization of borders adjacent to the mediastinum and 
chest wall. DW MRI could be a future good tool for proper 
staging and guidance of radiotherapy in NSCLC cases 
indicated for chemo/radiation. 
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Purpose or Objective: Purpose: The aim of this work was to 
compare the patterns of NSCLC relapses after combined 
modality therapy with postoperative hypofractionated and 
conventionally fractionated radiotherapy and after sugery 
 
Material and Methods: Material/methods. We treated 528 
patients between January 1990 and January 2014 (men – 445, 
women – 83) aged 27-78 years (median age 59) with 
morphologically proven NSCLC (adenocarcinoma - 161, 
squamous cell cancer– 289, other types – 70 patients); stage 
I-126, stage II - 117, III - 111. All patients were operated: 
pnevmonectomy -180, lobe/belobectomy – 304, 
segmentectomy – 30, wedge resection -11. 227 patients 
received neoadjuvant or adjuvant platinum-based 
chemotherapy. Three groups were retrospectively analyzed: 
group I - 174 patients without postoperative radiotherapy 
(PORT), group II - 180 patients with postoperative 
hypofractionated radiotherapy with daily dose 3Gy up to the 
total dose 36Gy-39Gy (EQD2=43-47Gy, α/β=3) and group III - 
174 patients with postoperative radiotherapy with daily dose 
2Gy up to the total dose 44Gy. Bronchial stump, involved 
regional lymphatic nodes and uninvolved groups (2R, 2L, 3a, 
3p, 4R, 4L, 5, 6, 7 according to IASLC classification) were 
included in the CTV. The groups were comparable in the 
following parameters: age, ECOG status, stage, T- and N - 
classification and the proportion of the patients treated with 
chemotherapy. The duration of the follow-up was 0,33-16,0 
years, median - 2,25 years. The relapses were classified as 
local (in bronchial stump), regional, or distant. In the cases 
of mixt relapses (local ± regional ±distant) they were 
included in each category. 
 
Results: Results. 263(49,8%) patients relapsed: 231 (43,8%) 
had distant metastases, local relapse – 51 (9,7%), regional 
relapse – 54 (10,2%). The pattern of the relapses in each 
group is presented in the table. 
 
 
 
Conclusion: Conclusion. Hypofractionated postoperative 
radiotherapy (daily dose 3Gy, total dose 36-39Gy) 
significantly decrease the probability of local and regional 
relapse in NSCLC patients as well as the total number of the 
relapses without any effect with regard to distant 
metastases. Hypofractionated PORT is equally effective as 
conventional PORT (daily dose 2Gy, total dose 44Gy) with 
regard to locoregional control but has the clear logistical 
advantage. 
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Purpose or Objective: Increasing the radiotherapy dose can 
result in improved local control for non-small-cell lung cancer 
(NSCLC) and can thereby improve survival. This can be 
compromised by accelerated repopulation of tumour cells 
during radiotherapy. Accelerated hypofractionated 
radiotherapy (AHRT) can expose tumors to a high dose of 
radiation in a short period of time. We have employed this 
approach in two groups of NSCLC: 1) early stage NSCLC 
patients who cannot tolerate the SABR treatment process (for 
example, extended periods in the treatment position) or who 
cannot travel to a centre with SABR; and 2) stage III NSCLC 
unfit for concurrent chemotheraphy.  
This study was performed to evaluate the feasibility of 
utilizing AHRT for these patients. 
 
Material and Methods: 76 patients (46 stage I-II and 30 local 
advanced NSCLC) were included. All patients had FDG-PET 
scan. Only the primary tumour and the positive mediastinal 
areas on the pre-treatmement FDG-PET scan were irradiated. 
Mean age was 77.9 ± 7.9 years. The performance status (PS) 
was > 2 in 50% of cases. The radiotherapy was delivered in 
2.75 Gy fractions, once daily to a total dose of 66 Gy (BED10: 
84 Gy). Sequential chemotheraphy (mainly platinum and 
vinorelbine) was administered in 95% of stage III patients. 
Acute/late toxicity was evaluated using the RTOG criteria. 
 
Results: After a mean follow-up of 2 years, the median 
overall survival (OS) and cause specific survival (CSS) were 23 
and 54 months, respectively. On multivariate Cox regression 
analysis, PS >2 was an independent risk factor for OS 
(p<0.0001) and CSS (p<0.0001). The major acute adverse 
reactions were grade 2 dermitis (18%), grade 2 esophagitis 
(10%) and grade 1 pneumonitis (26%). There were 34 patients 
with grade 1 late pneumonitis. 
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Conclusion: AHRT is a reasonable alternative to conventional 
fractionated radiotherapy in stage I-II NSCLC without access 
to SABR and in stage III patients unfit for concurrent 
chemotheraphy. In both groups, treatment was well tolerated 
without grade 3 or higher treatment-related toxicity. PS >2 
was an independent risk factor for OS and CSS. 
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Purpose or Objective: Since 2014, the VERO system 
equipped with dynamic tracking DT has been used in our 
center for lung SBRT.The purpose of this work is to compare 
2 compensation techniques for lung SBRT, DT and a method 
based on the definition of an ITV, in terms of PTV volume 
reduction and treatment time. 
 
Material and Methods: The VERO is an O ring system 
equipped with a gimbaled linac allowing pan and tilt 
rotations and with a stereoscopic dual-source kV X-ray 
imaging allowing the guidance of the tracking. A 4DCT is done 
to measure the range of the target movements with the 
breath: if the amplitude is < 7mm, an ITV is determined on 
the MIP images and if it is > 7mm, the DT method is 
preferred. A gold marker (Visicoil, IBA) is then implanted in 
the lesion and a new 4DCT is realized 1 week later. The 
GTVDT is drawn on the exhale phase and the PTVDT is 
defined with a 5mm margin. The dose is prescribed on the 
isodose covering 95 % of the PTV (Monte Carlo): the 
peripheral tumors receive 3x17 Gy, near the thoracic wall 
4x12 Gy and near the mediastin 8x7,5 Gy. The metastatic 
diseases received 5x10 Gy. For DT, treatments are delivered 
with 6-8 no coplanar beams. 
 
Results: 77 patients were treated with lung SBRT, including 
22 patients treated with DT. Among these 22 patients, the 
PTVITV was however estimated: the average size of the 
PTVDT was 28.8cc(6.5 - 14.3 cc) and that of the PTVITV was 
46.4cc(10.4 in 139 cc), so a 40 % reduction of the PTV 
volume. The average session length in DT was 35 min, the 
same as with the ITV method. The breathing rate of the 
patients was often irregular during the session and especially 
compared with the reference 4DCT. It did not affect the 
treatment delivery neither the guidance of the tracking. The 
clinical tolerance during and after the SBRT with tracking was 
excellent: 1 patient that was already treated for interstitial 
pulmonary fibrosis developed symptomatic radiation 
pneumonitis (RP). 5 other patients had radiological RP on the 
CT done during their first 6 months follow up period ; all of 
them received corticosteroid therapy and did not show any 
symptoms. There was no chest wall toxicity. Over a 16 
months follow-up,1 patient did not benefit from treatment 
with DT SBRT and had a progressive disease. 
 
Conclusion: With a 40% reduction of the PTV, this DT 
technique makes it easy to monitor all the patients breathing 
motion, including very irregular rates, in a treatment time 
equivalent to more classical techniques based on the ITV. 
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Purpose or Objective: Local failure in lung cancer is 
associated with extremely poor survival. This study tested 
whether the pattern of failure is associated with the most 
PET avid volume in the pre-therapeutic PET/CT scan. 
 
Material and Methods: Patients with inoperable NSCLC 
treated in our department between 2008 and 2010 were 
reviewed. Forty patients, who received radiotherapy (RT) for 
NSCLC and had an accessible pre-therapeutic FDG PET/CT 
scanning, were included. Fifteen of the patients developed 
local failure as the first event. Patient and tumour 
characteristics for patients with recurrences are presented in 
Table 1. The peak SUV area in the pre-therapeutic PET/CT 
scan in both tumor and lymph nodes were identified by an 
experienced nuclear physician who delineated the volume 
encompassing 50% of the maximum SUV (SUVmax50) in all 
fifteen patients. All patients were followed by CT scans every 
third month. The CT scans which showed recurrences (rCT) 
were imported to the Eclipse treatment planning system 
(Varian MS) and the recurrence gross tumor volume(s) (rGTV) 
was delineated. A rigid registration between pre-therapeutic 
PET/CT and treatment planning CT (pCT) was performed 
using a soft tissue match on the tumor or the lymph nodes in 
SmartAdapt (Varian MS). The SUVmax50 volumes were copied 
to pCT using the rigid registration. The rCT with the defined 
rGTV were also fused with the pCT using a rigid registration 
based on normal tissue nearby the rGTV but excluding the 
rGTV. The vertebral column or the aortic arch was found to 
be preferable. Two radiation oncologists assessed the rigid 
registration between pCT and rCT. 
 
Results: The patients received conventionally fractionated 
RT with a total dose of 60-66 Gy. Planning target volumes 
(PTV) ranged from 169 cm3 to 1065 cm3 (mean = 678 cm3). 
Median time to local progression was seven months (95% CI 5-
9 months). In twelve patients, the recurrences of the primary 
tumor appeared inside the PTV. In three cases, the 
recurrences were both inside and outside the PTV. These 
three recurrences outside the PTV appeared in mediastinal 
lymph node region. The rGTV overlapped with the pre-
therapeutic PET sub-volumes in twelve patients (Figure 1). In 
one case, rGTV was near the PET sub-volume area without 
overlapping. In one patient, part of the target was missed 
because an atelectasis obscured the PET/CT signal and made 
the delineation of GTV less optimal. 
 
 
